Apr 29 |
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
|
Apr 25 |
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
|
Apr 15 |
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
|
Apr 3 |
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
|
Apr 1 |
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV
|
Mar 28 |
Can-Fite Biopharma GAAP EPS of -$0.01, revenue of $0.74M
|
Mar 28 |
Can-Fite Reports 2023 Financial Results and Clinical Update
|
Mar 11 |
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
|
Feb 28 |
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
|
Jan 30 |
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
|